Literature DB >> 26066768

Aminolevulinic acid dendrimers in photodynamic treatment of cancer and atheromatous disease.

L Rodriguez1, P Vallecorsa, S Battah, G Di Venosa, G Calvo, L Mamone, D Sáenz, M C Gonzalez, A Batlle, A J MacRobert, A Casas.   

Abstract

The use of endogenous protoporphyrin IX after administration of 5-aminolaevulinic acid (ALA) has led to many applications in photodynamic therapy (PDT). We have previously reported that the conjugation of ALA dendrimers enhances porphyrin synthesis. The first aim of this work was to evaluate the ability of ALA dendrimers carrying 6 and 9 ALA residues (6m-ALA and 9m-ALA) to photosensitise cancer cells. For this aim, we employed LM3 mammary carcinoma cells. In these tumour cells, at low concentrations porphyrin synthesis from dendrimers was higher compared to ALA, whereas at high concentrations, porphyrin synthesis was similar from both compounds. Topical application of ALA dendrimers on the skin overlying a subcutaneous LM3 implanted tumour showed no diffusion of the molecules either to distant skin sites or to the adjacent tumour, suggesting a promising use of the ALA macromolecules in superficial cancer models. As a second objective, we proposed the use of ALA-dendrimers in vascular PDT for the treatment of atherosclerosis. Thus, we focused our studies on ALA-dendrimer's selectivity towards macrophages in comparison with endothelial cells. For this aim we employed Raw 264.7 macrophages and HMEC-1 microvasculature cells. Porphyrin synthesis induced in macrophages by 6m-ALA and 9m-ALA (3 h, 0.025 mM) was 6 and 4.6 times higher respectively compared to the endothelial cell line, demonstrating the high affinity of ALA dendrimers for macrophages. On the other hand, ALA employed at low concentrations was slightly selective (1.7-fold) for macrophages. Inhibition studies suggested that ALA dendrimer uptake in macrophages is mainly mediated by caveloae-mediated endocytosis. Our main conclusion is that in addition to being promising molecules in PDT of superficial cancer, ALA dendrimers may also find applications in vascular PDT, since in vitro they showed selectivity to the macrophage component of the atheromatous plaque, as compared to the vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26066768     DOI: 10.1039/c5pp00126a

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  6 in total

1.  Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy.

Authors:  Connor Thunshelle; Rui Yin; Qiquan Chen; Michael R Hamblin
Journal:  Curr Dermatol Rep       Date:  2016-07-13

2.  Apoptotic cell death induced by dendritic derivatives of aminolevulinic acid in endothelial and foam cells co-cultures.

Authors:  Mariela A Céspedes; Daniel A Saénz; Gustavo H Calvo; Marina González; Alexander J MacRobert; Sinan Battah; Adriana G Casas; Gabriela M Di Venosa
Journal:  Photochem Photobiol Sci       Date:  2021-04-06       Impact factor: 3.982

3.  Small molecule additive enhances cell uptake of 5-aminolevulinic acid and conversion to protoporphyrin IX.

Authors:  Kara M Harmatys; Anthony J Musso; Kasey J Clear; Bradley D Smith
Journal:  Photochem Photobiol Sci       Date:  2016-11-02       Impact factor: 3.982

4.  Novel meso-substituted porphyrin derivatives and its potential use in photodynamic therapy of cancer.

Authors:  Pablo Vallecorsa; Gabriela Di Venosa; M Belén Ballatore; Dario Ferreyra; Leandro Mamone; Daniel Sáenz; Gustavo Calvo; Edgardo Durantini; Adriana Casas
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.430

Review 5.  Immunotoxicity Considerations for Next Generation Cancer Nanomedicines.

Authors:  Gary Hannon; Joanne Lysaght; Neill J Liptrott; Adriele Prina-Mello
Journal:  Adv Sci (Weinh)       Date:  2019-08-01       Impact factor: 16.806

Review 6.  Nanoformulation of Tetrapyrroles Derivatives in Photodynamic Therapy: A Focus on Bacteriochlorin.

Authors:  Pragya Pallavi; Karthick Harini; Vijaya Anand Arumugam; Pemula Gowtham; Koyeli Girigoswami; Saradhadevi Muthukrishnan; Agnishwar Girigoswami
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-30       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.